LI Yan
Principal Investigator
Li Yan is mainly engaged in molecular pharmacology research of anti-tumor drugs and the development of new drugs for many years, including the establishment of drug screening models and compounds screening, targets confirmation, and in-depth pharmacodynamic evaluation of active compounds. Her research is mainly focused on the impact of tumor metabolism changes mediated by kinases on the tumor microenvironment, and combining network pharmacology, transcriptomics, proteomics, molecular probes and other methods, she explores the anti-tumor targets and network regulation mechanisms of natural products and traditional Chinese medicine compounds, and evaluation of their preclinical efficacy at the molecular level, cellular level and animal level.
1. Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-κB and STAT3 inhibitors. Bioorg Chem, 2021 Jun;111:104973. doi: 10.1016/j.bioorg.2021.104973.
2. Discovery of CAPE derivatives as dual EGFR and CSK inhibitors with anticancer activity in a murine model of hepatocellular carcinoma. Bioorg Chem. 2021 Feb;107:104536. doi:10.1016/j.bioorg.2020.104536.
3. Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones. Bioorganic & Medicinal Chemistry. 2020;28(13):115557.
4. Ginsenoside 3β-O-Glc-DM (C3DM) enhanced the antitumor activity of Taxol on Lewis lung cancer by targeting the IL-6/Jak2/STAT3 and IL-6/AKT signaling pathways. World J Tradit Chin Med. 2020;6:432-440.
5. The antitumor activity and mechanism of MCL3 in G422 glioblastoma. World J Tradit Chin Med. 2020;6:353-361.
6. Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine. Current Pharmaceutical Design. 2019; 25(13):3578-3589.
7. The effects and mechanisms of a biosynthetic ginsenoside 3β,12β-Di-O-Glc-PPD on non-small cell lung cancer. Onco Targets Ther. 2019;12:7375-7385.
